DEXCOM INC (DXCM) Stock News
NASDAQ:DXCM - Nasdaq - US2521311074 - Common Stock - Currency: USD
DXCM Latest News, Press Relases and Analysis
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM)...
2 Cash-Producing Stocks That Stand Out and 1 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
3 New ETFs Finding Early Traction With Investors
Markets have tumbled in 2025, but three funds launched this year have the potential to outshine even longer-established ETFs.
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
Amazon (AMZN) Price Target Slashed by Investment Bank, But Bullish Outlook Maintained
Investment bank Piper Sandler today cut its price target on Amazon (AMZN) to $215 from $265 but kept an Overweight rating on the name. Piper expects the tech giant to provide fairly upbeat guidance when it reports its first-quarter results within the next few weeks. A Look at Piper’s Estimates for AMZN Piper expects Amazon […]
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
Mentions: GOOG
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
For those who can afford it without blowing their budget, it's actually a great idea to pick up shares of top companies on the dip during a correction. With that in mind, here are two excellent growth-oriented companies to buy in the ongoing market meltdown: tech giant Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) and medical device maker DexCom (NASDAQ: DXCM).
Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device
Dexcom stock surged Thursday after the FDA cleared its newest diabetes device for an extended 15-day wear time.
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells us that equities tend to experience strong runs following downturns, so it's worth putting money into excellent companies that are being dragged down with along with the broader market. To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), Vertex Pharmaceuticals (NASDAQ: VRTX), Intuitive Surgical (NASDAQ: ISRG), and Shopify (NASDAQ: SHOP).
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8% (net) in the fourth […]
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
